Gastrointestinal events remain the most commonly reported adverse events in patients starting methotrexate therapy for rheumatoid arthritis, according to a new review and pooled analysis. The analysis also identified several factors associated with treatment discontinuation and the risk of elevated liver enzymes. “Identifying predictors of adverse events can help individualise therapy, promote adherence, and subsequently ...
New review of MTX adverse events can inform patients when starting therapy
By Dave Levitan
10 May 2021